LIXIL-JS-FOUNDATION
The LIXIL JS Foundation (located in Koto-ku, Tokyo; Chairperson: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, conducted the Open Final Screening for the 6th LIXIL International Student Architectural Competition at the Keidanren Kaikan (Chiyoda-ku, Tokyo) on July 20, 2016 (Wed). The purpose of the competition is to seek and review next-generation sustainable housing technology and communicate that technology to the global society. The top three universities chosen from twelve participating universities in ten countries gave presentations, and INFINITE FIELD by Royal Danish Academy of Fine Arts (Denmark) was selected as the winner.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160726006668/en/
During the Open Final Screening, a heated discussion occurred between the head of jury, Kengo Kuma (Architect/ Professor, the University of Tokyo) and jurors, Tomonari Yashiro (Professor, Institute of Industrial Science, the University of Tokyo/ Vice President, the University of Tokyo), Masato Araya (Structural Designer/ Professor Emeritus, Waseda University), Yoshiharu Tsukamoto (Architect/ Co-founder of Atelier Bow-Wow/ Professor, Graduate school of Tokyo Institute of Technology) and Dana Buntrock (Architect, Department of Architecture, University of California, Berkeley). The theme of the 6th competition was “Comfort and Lightness.” As the competition’s first attempt, the contestants proposed a light shelter, which can be easily assembled and moved. This time around, as another first attempt, their mockups were actually brought in and exhibited at the hall for the final screening.
Royal Danish Academy of Fine Arts’ INFINITE FIELD was highly rated in various aspects, including a whole new architectural approach that can safely be referred to as an extension of “furniture” that gives consideration even to the form created by the human body and wood, a high degree of perfection of details, including materials to be cut and assembled, and a 360 degree open design that can become a big appeal when installed in Taiki-cho, Hokkaido.
In his general comments, the head juror, Kengo Kuma said, “Screening by using mockups was something innovative that I had never experienced and it gave the students a good opportunity to think about architecture starting with materials. Moreover, this competition was valuable also from a perspective of architectural culture in that their work remains.” At the award ceremony, Mr. Konstatinos Fetsis of Royal Danish Academy of Fine Arts commented, “I am very pleased to have been able to take part in this competition and this journey with these members. This has become such a wonderful experience that I will never forget as a student who majors in architecture.”
With support from Kengo Kuma & Associates, the team will arrive at a final design for “INFINITE FIELD,” and the project is scheduled to be built in October 2016 on a site at Memu Meadows, located in Taiki-cho, Hokkaido.
[Reference Information]
List of Winning Works
-
Top Prize
INFINITE FIELD by Royal Danish Academy
of Fine Arts
- Award of Excellence (2 works)
LEVITATING
ATMOSPHERES by HESAM University / ENSA Paris-La-Villette
Light Skin
HOUSE by Yokohama National University
6th LIXIL International Student Architectural Competition
Theme:
Comfort and Lightness
The contemporary concept of comfort
hinges on blocking out the environment and creating barriers. But
perhaps what we really need today is to live in closer proximity to
nature. Please design a light shelter, one which can be easily assembled
and moved, and also allows residents to enjoy a comfortable life. The
ability to move the house means interpreting, considering, and creating
a relationship with its surroundings. And the ability to easily assemble
means it can become linked with the natural environment and ground, and
draw out the richness of the place. Please devise a house that can be
easily assembled and moved, and will allow the residents to enjoy the
environment, both the summer and winter in Taiki-cho, Hokkaido. The
relationship with nature and the surrounding area in your proposal might
also include a method of interpreting the environment if the house was
relocated to a city.
1. Participating universities:
12 universities in 10 countries
*
The three universities marked with X proceeded to the Open Final
Screening held on July 20, 2016.
Cornell University (USA) | ||
Parsons School of Design (USA) | ||
Universidad Nacional Autónoma de México (México) | ||
X |
Royal Danish Academy of Fine Arts (Denmark) |
|
Polytechnic of Milan (Italy) | ||
X |
HESAM University / ENSA Paris-La-Villette (France) |
|
Swiss Federal Institute of Technology (ETH) Zurich (Switzerland) | ||
University of Melbourne (Australia) | ||
Chulalongkorn University (Thailand) | ||
University of Cape Town (South Africa) | ||
Kyoto Institute of Technology (Japan) | ||
X |
Yokohama National University (Japan) |
|
2. Judging method
Twelve universities in ten countries were
invited to submit proposals for a next-generation, sustainable house
designed for a cold region. Three entrants were then selected in the
first screening (based on documents submitted). The top prize winner was
subsequently chosen in the Open Final Screening.
3. Jury:
Kengo Kuma (Professor at the Graduate School of
Architecture, The University of Tokyo)
Tomonari Yashiro (Deputy
Director and Professor at the Institute of Industrial Science, The
University of Tokyo)
Masato Araya (Structural Engineer, Professor
Emeritus at Waseda University)
Yoshiharu Tsukamoto (Professor at
Tokyo Institute of Technology, Co-Principal of Atelier Bow-Wow)
Dana
Buntrock (Professor at Department of Architecture, University of
California, Berkeley)
4. Prizes
Top prize (one work): $15,000 (USD; including
design fee)
Award of Excellence (two works): $3,000
*The winner’s work “INFINITE FIELD” will be built on a site at Memu Meadows, located in Taiki-cho, Hokkaido (to be completed in October 2016).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160726006668/en/
Contact:
LIXIL JS Foundation
Kumeo Takahata, +81(0)3-5626-1008
2-1-1,
Oshima, Koto-ku, Tokyo 136-8535
LIXIL JS Foundation website: http://www.lixiljsfound.com/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom